Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
复制标题
使用单克隆抗组织型纤溶酶原激活剂抗体，通过组织型纤溶酶原激活剂抗原和功能的组合测定系统评估纤溶能力。
DOI：
--
复制
发表时间：
1987
期刊：
影响因子：
--
通讯作者：
B. Binder
中科院分区：
文献类型：
--
作者：
J. Wojta;L. Turcu;O. Wagner;C. Korninger;B. Binder
已经开发出一种检测系统，可以连续定量同一血浆样本中的组织型纤溶酶原激活剂 (t-PA) 活性和 t-PA 抗原。在第一步中，t-PA 与固定化的 IgM 单克隆抗 t-PA 抗体结合，结合的 t-PA 的功能活性通过其纤溶酶原激活活性进行定量。在第二步中，使用不同的过氧化物酶标记的单克隆抗 t-PA 抗体测定结合的 t-PA 抗原的量。在该组合测定系统中，发现 t-PA 功能活性不仅取决于 t-PA 抗原的量，还取决于纤溶酶原激活剂抑制剂 (PAI) 的量，而在 t-PA 抗原测定中，PAI 并不影响结果。在从正常对照获得的血浆样品中，仅在静脉闭塞后血浆中检测到 t-PA 活性 (3.7 +/- 2.5 IU/ml)，而在静脉闭塞之前发现 2.7 +/- 0.5 ng/ml t-PA 抗原，在静脉闭塞后发现 12.6 +/- 4.4 ng/ml。使用这种组合测定系统来研究对静脉闭塞无反应的患者的血浆样本，并缩短优球蛋白凝块溶解时间（ECLT），不仅可以确认这些患者中没有一个在闭塞后血浆样本中检测到t-PA活性，而且还可以将该组患者细分为约39%的患者组，该组患者对静脉闭塞的正常t-PA抗原释放不反应，以及第二组约61%与正常的 t-PA 抗原释放发生反应。（摘要截断为 250 字）
An assay system has been developed that allows consecutive quantification of tissue-type plasminogen activator (t-PA) activity and t-PA antigen in the same plasma sample. In the first step t-PA is bound to an immobilized IgM monoclonal anti-t-PA antibody and functional activity of bound t-PA is quantified by its plasminogen-activating activity. In the second step the amount of bound t-PA antigen is determined by using a different peroxidase-labeled monoclonal anti-t-PA antibody. In this combined assay system t-PA functional activity was found to depend not only on the amount of t-PA antigen but also on the amount of plasminogen activator inhibitor (PAI), whereas in the t-PA antigen assay PAI did not affect the results. In plasma samples obtained from normal controls t-PA activity was detected only in post-venous occlusion plasma (3.7 +/- 2.5 IU/ml), whereas 2.7 +/- 0.5 ng/ml t-PA antigen was found before and 12.6 +/- 4.4 ng/ml after venous occlusion. Using this combined assay system to study plasma samples from patients who did not respond to venous occlusion with shortening of the euglobulin clot lysis time (ECLT), it was possible not only to confirm that in none of these patients could t-PA activity be detected in the postocclusion plasma samples but also to subdivide that group of patients into a group of about 39% not reacting with normal t-PA antigen release to venous occlusion and into a second group of about 61% that reacted with normal t-PA antigen release.(ABSTRACT TRUNCATED AT 250 WORDS)